Colon cancer (CC) is an immunogenic tumor and immune-targeting disease. In this study, we analyzed differentially expressed genes (DEGs) from the expression profile data in CC of The Cancer Genome Atlas.
Methods and Results:
Using univariate and multivariate Cox regression analysis, an immune gene-risk model containing 14 immune genes was established. Four hundred seventeen CC samples were divided into high-risk and low-risk groups, and Kaplan-Meier analysis revealed that high-risk score predicted poor survival. Meanwhile, we found the model was an independent prognostic factor for CC. Weighted gene coexpression network analysis was used to identify key gene modules between high- and low-risk groups. The methods of CIBERSORT and single-sample Gene Set Enrichment Analysis were used to evaluate the correlation between immune cells and our model.
Conclusion:
Taken together, our study suggested that the immune gene-related risk model may be developed as a potential tool in the prognostic assessment of CC
Get full access to this article
View all access options for this article.
References
1.
BeckerC, FantiniMC, SchrammC, et al. (2004) TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity, 21:491-501.
2.
BeckerN (2003) [Epidemiology of colorectal cancer]. Radiologe, 43:98-104.
3.
BhattacharyaS, AndorfS, GomesL, et al. (2014) ImmPort: disseminating data to the public for the future of immunology. Immunol Res, 58:234-239.
4.
BlumJS, WearschPA, CresswellPJ (2013) Pathways of antigen processing. Annu Rev Immunol, 31:443-473.
5.
ChaeSC, YuJI, UhmTB, et al. (2012) The haplotypes of TNFRSF17 polymorphisms are associated with colon cancer in a Korean population. Int J Colorectal Dis, 27:701-707.
6.
CharoentongP, FinotelloF, AngelovaM, et al. (2017) Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep, 18:248-262.
7.
ChenH, LuoJ, GuoJ (2020) Development and validation of a five-immune gene prognostic risk model in colon cancer. BMC Cancer, 20:395.
8.
ChinCH, ChenSH, WuHH, et al. (2014) cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol 8 Suppl, 4:S11.
9.
CrottyS (2015) A brief history of T cell help to B cells. Nat Rev Immunol, 15:185-189.
10.
DaniC (2013) Activins in adipogenesis and obesity. Int J Obes (Lond), 37:163-166.
11.
DevineRD, BicerS, ReiserPJ, et al. (2017) Increased hypoxia-inducible factor-1α in striated muscle of tumor-bearing mice. Am J Physiol Heart Circ Physiol, 312:H1154-H1162.
12.
DoaeiS, HajiesmaeilM, AminifardA, et al. (2018) Effects of gene polymorphisms of metabolic enzymes on the association between red and processed meat consumption and the development of colon cancer; a literature review. J Nutr Sci, 7:e26.
13.
DruckerDJ, YustaB (2014) Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol, 76:561-583.
14.
DucarougeB, Pelissier-RotaM, PowellR, et al. (2017) Involvement of CRF2 signaling in enterocyte differentiation. World J Gastroenterol, 23:5127-5145.
15.
GermannM, ZanggerN, SauvainMO, et al. (2020) Neutrophils suppress tumor-infiltrating T cells in colon cancer via matrix metalloproteinase-mediated activation of TGFbeta. EMBO Mol Med, 12:e10681.
16.
GongYZ, RuanGT, LiaoXW, et al. (2019) Diagnostic and prognostic values of integrin alpha subfamily mRNA expression in colon adenocarcinoma. Oncol Rep, 42:923-936.
17.
Gonzalez-DuqueS, AzouryME, ColliML, et al. (2018) Conventional and neo-antigenic peptides presented by β cells are targeted by circulating naïve CD8+ T cells in type 1 diabetic and healthy donors. Cell Metab, 28:946-960.e6.
18.
GorbenkoO, PanayotouG, ZhyvoloupA, et al. (2010) Identification of novel PTEN-binding partners: PTEN interaction with fatty acid binding protein FABP4. Mol Cell Biochem, 337:299-305.
19.
GretenFR, EckmannL, GretenTF, et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118:285-296.
20.
HacklH, CharoentongP, FinotelloF, et al. (2016) Computational genomics tools for dissecting tumour-immune cell interactions. Nat Rev Genet, 17:441-458.
21.
Hayes-JordanAA, SandlerG, MalakornS, et al. (2020) Colon cancer in patients under 25 years old: a different disease?. J Am Coll Surg, 230:648-656.
22.
HeagertyPJ, LumleyT, PepeMS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics, 56:337-344.
HuangC, LuJ, ZhengCH, et al. (2017) Prognostic significance of perigastric tumor deposits in patients with primary gastric cancer. Ann Oncol 28 Suppl, 3:iii47.
25.
JiaQ, WuW, WangY, et al. (2018) Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun, 9:5361.
26.
JiangL, HermekingH (2017) miR-34a and miR-34b/c suppress intestinal tumorigenesis. Cancer Res, 77:2746-2758.
27.
KeJ, LiuXH, JiangXF, et al. (2020) Immune-related gene signature in predicting prognosis of early-stage colorectal cancer patients. Eur J Surg Oncol, 46:e62-e70.
28.
KongJC, GuerraGR, PhamT, et al. (2019) Prognostic impact of tumor-infiltrating lymphocytes in primary and metastatic colorectal cancer: a systematic review and meta-analysis. Dis Colon Rectum, 62:498-508.
29.
LangfelderP, HorvathS (2008) WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics, 9:559.
30.
LiF, LuL, PengY, et al. (2017) Increased GLP2R expression in gastric chief cells of patients with severe obesity regardless of diabetes status. Int J Obes (Lond), 41:1303-1305.
31.
LiX, WenD, LiX, et al. (2020) Identification of an immune signature predicting prognosis risk and lymphocyte infiltration in colon cancer. Front Immunol, 11:1678.
32.
LongT, LiuZ, ZhouX, et al. (2019) Identification of differentially expressed genes and enriched pathways in lung cancer using bioinformatics analysis. Mol Med Rep, 19:2029-2040.
Murrell P (2005) R Graphics (Computer Science and Data Analysis). Chapman & Hall/CRC, Boca Raton.
35.
NajafiM, GoradelNH, FarhoodB, et al. (2019) Tumor microenvironment: interactions and therapy. J Cell Physiol, 234:5700-5721.
36.
NeurathMF (2019) IL-23 in inflammatory bowel diseases and colon cancer. Cytokine Growth Factor Rev, 45:1-8.
37.
NewmanAM, LiuCL, GreenMR, et al. (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods, 12:453-457.
38.
PanY, TianT, ParkCO, et al. (2017) Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism. Nature, 543:252-256.
39.
PelusoG, IncollingoP, CalogeroA, et al. (2017) Current tissue molecular markers in colorectal cancer: a literature review. Biomed Res Int, 2017:2605628.
QuY, ZhaoG, LiH (2017) Forward and reverse signaling mediated by transmembrane tumor necrosis factor-alpha and TNF receptor 2: potential roles in an immunosuppressive tumor microenvironment. Front Immunol, 8:1675.
42.
RammerM, WebersinkeG, Haitchi-PetnehazyS, et al. (2017) MicroRNAs and their role for T stage determination and lymph node metastasis in early colon carcinoma. Clin Exp Metastasis, 34:431-440.
43.
RitchieME, PhipsonB, WuD, et al. (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 43:e47.
44.
SalmonH, FranciszkiewiczK, DamotteD, et al. (2012) Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest, 122:899-910.
45.
ShahYM, MorimuraK, GonzalezFJ (2007) Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally induced colitis. Am J Physiol Gastrointest Liver Physiol, 292:G657-G666.
46.
ShannonP, MarkielA, OzierO, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res, 13:2498-2504.
47.
ShengY, LiF, QinZ (2018) TNF receptor 2 makes tumor necrosis factor a friend of tumors. Front Immunol, 9:1170.
48.
SiegelRL, FedewaSA, AndersonWF, et al. (2017) Colorectal cancer incidence patterns in the United States, 1974-2013. J Natl Cancer Inst, 109:djw322.
49.
SungH, SiegelRL, RosenbergPS, et al. (2019) Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health, 4:e137-e147.
50.
TangZ, LiC, KangB, et al. (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res, 45:W98-W102.
51.
WangLY, JiangJ, MaHM (2015) Molecular characterization, tissue expression profile, and SNP analysis of porcine SLC13A5. Genet Mol Res, 14:16090-16101.
52.
WangZ, SongQ, YangZ, et al. (2019) Construction of immune-related risk signature for renal papillary cell carcinoma. Cancer Med, 8:289-304.
53.
WeinbergRA, WeinbergRA (2013) The Biology of Cancer. Garland Science, New York.
54.
WismannP, BarkholtP, SecherT, et al. (2017) The endogenous preproglucagon system is not essential for gut growth homeostasis in mice. Mol Metab, 6:681-692.
55.
XiaoK, LiuQ, PengG, et al. (2020) Identification and validation of a three-gene signature as a candidate prognostic biomarker for lower grade glioma. PeerJ, 8:e8312.
56.
YaegerR, ChatilaWK, LipsycMD, et al. (2018) Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell, 33:125-136.e3.
57.
YangH, JinW, LiuH, et al. (2020) Immune-related prognostic model in colon cancer: a gene expression-based study. Front Genet, 11:401.
58.
YangL, CuiJ, WangY, et al. (2019) FAM83H-AS1 is upregulated and predicts poor prognosis in colon cancer. Biomed Pharmacother, 118:109342.
59.
YuG, WangLG, HanY, et al. (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS, 16:284-287.
60.
ZambonelliP, GaffoE, ZappaterraM, et al. (2016) Transcriptional profiling of subcutaneous adipose tissue in Italian Large White pigs divergent for backfat thickness. Anim Genet, 47:306-323.
61.
ZhangM, ZhuK, PuH, et al. (2019) An immune-related signature predicts survival in patients with lung adenocarcinoma. Front Oncol, 9:1314.
62.
ZhouZ, LuZR (2017) Molecular imaging of the tumor microenvironment. Adv Drug Deliv Rev, 113:24-48.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
